- Home
- NOTE vs STTK Comparison
NOTE vs STTK Comparison
Compare NOTE & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- STTK
- Stock Information
- Founded
- NOTE 2013
- STTK 2016
- Country
- NOTE United States
- STTK United States
- Employees
- NOTE N/A
- STTK N/A
- Industry
- NOTE EDP Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NOTE Technology
- STTK Health Care
- Exchange
- NOTE Nasdaq
- STTK Nasdaq
- Market Cap
- NOTE 83.1M
- STTK 83.8M
- IPO Year
- NOTE N/A
- STTK 2020
- Fundamental
- Price
- NOTE $4.58
- STTK $1.92
- Analyst Decision
- NOTE Strong Buy
- STTK Hold
- Analyst Count
- NOTE 4
- STTK 6
- Target Price
- NOTE $29.25
- STTK $2.67
- AVG Volume (30 Days)
- NOTE 322.8K
- STTK 1.6M
- Earning Date
- NOTE 11-11-2025
- STTK 11-13-2025
- Dividend Yield
- NOTE N/A
- STTK N/A
- EPS Growth
- NOTE N/A
- STTK N/A
- EPS
- NOTE N/A
- STTK N/A
- Revenue
- NOTE $109,683,000.00
- STTK $2,997,000.00
- Revenue This Year
- NOTE N/A
- STTK N/A
- Revenue Next Year
- NOTE $42.27
- STTK N/A
- P/E Ratio
- NOTE N/A
- STTK N/A
- Revenue Growth
- NOTE N/A
- STTK N/A
- 52 Week Low
- NOTE $3.80
- STTK $0.69
- 52 Week High
- NOTE $24.36
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- NOTE 37.13
- STTK 72.13
- Support Level
- NOTE $3.80
- STTK $1.68
- Resistance Level
- NOTE $5.48
- STTK $2.04
- Average True Range (ATR)
- NOTE 0.59
- STTK 0.19
- MACD
- NOTE 0.06
- STTK 0.09
- Stochastic Oscillator
- NOTE 42.40
- STTK 89.29
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.